TG Therapeutics (NASDAQ:TGTX) Now Covered by Analysts at TD Cowen

TD Cowen started coverage on shares of TG Therapeutics (NASDAQ:TGTX) in a research report released on Tuesday morning, MarketBeat Ratings reports. The brokerage issued a buy rating and a $50.00 target price on the biopharmaceutical company’s stock.

A number of other equities analysts also recently issued reports on TGTX. The Goldman Sachs Group increased their price target on shares of TG Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. B. Riley increased their price target on shares of TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $49.00 price target on shares of TG Therapeutics in a research note on Wednesday, September 18th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, TG Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $36.33.

TG Therapeutics Stock Performance

Shares of NASDAQ:TGTX opened at $26.90 on Tuesday. The company has a market cap of $4.16 billion, a price-to-earnings ratio of 44.10 and a beta of 2.21. The company has a 50-day moving average price of $23.51 and a 200-day moving average price of $20.01. The company has a current ratio of 3.58, a quick ratio of 2.83 and a debt-to-equity ratio of 0.58. TG Therapeutics has a 12 month low of $9.81 and a 12 month high of $26.99.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.08. TG Therapeutics had a net margin of 27.60% and a return on equity of 57.73%. The company had revenue of $73.47 million during the quarter, compared to the consensus estimate of $65.92 million. During the same period in the prior year, the firm earned ($0.34) earnings per share. TG Therapeutics’s revenue was up 357.0% on a year-over-year basis. As a group, equities analysts anticipate that TG Therapeutics will post 0.12 EPS for the current year.

Hedge Funds Weigh In On TG Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Marshall Wace LLP bought a new stake in shares of TG Therapeutics during the second quarter valued at approximately $36,501,000. Hood River Capital Management LLC bought a new stake in shares of TG Therapeutics during the first quarter valued at approximately $22,420,000. Principal Financial Group Inc. increased its position in shares of TG Therapeutics by 1,549.4% during the third quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company’s stock valued at $18,061,000 after acquiring an additional 725,371 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in shares of TG Therapeutics during the second quarter valued at approximately $10,423,000. Finally, Assenagon Asset Management S.A. bought a new stake in shares of TG Therapeutics during the second quarter valued at approximately $8,698,000. Institutional investors own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.